The Novel Phosphodiesterase Inhibitor NM-702 Improves Claudication-Limited Exercise Performance in Patients With Peripheral Arterial Disease
- 1 December 2006
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 48 (12) , 2539-2545
- https://doi.org/10.1016/j.jacc.2006.07.064
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Effect of Cilostazol on Treadmill Walking, Community‐Based Walking Ability, and Health‐Related Quality of Life in Patients with Intermittent Claudication Due to Peripheral Arterial Disease: Meta‐Analysis of Six Randomized Controlled TrialsJournal of the American Geriatrics Society, 2002
- Leg Symptoms in Peripheral Arterial DiseaseJAMA, 2001
- Medical Treatment of Peripheral Arterial Disease and ClaudicationNew England Journal of Medicine, 2001
- CilostazolDrugs & Aging, 1999
- Exercise Rehabilitation Programs for the Treatment of Claudication PainJAMA, 1995
- Clinical Trials for ClaudicationCirculation, 1995
- Effect of Diagnostic Criteria on the Prevalence of Peripheral Arterial DiseaseCirculation, 1995
- Pharmacological profiles of NM-702, a novel multiple inhibitor of cyclic-nucleotide phosphodiesterases and thromboxane A2 synthaseThe Japanese Journal of Pharmacology, 1995
- Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association September 18-20, 1992 New Orleans, Louisiana.Circulation, 1993
- Effect of Oral Milrinone on Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1991